Professional Documents
Culture Documents
The
protocols are listed by disease site.
Referal is ONLY by physician consultation sent to any of the physicians based at the
McGill University Hospitals.
SITE GI Investigator
Sub-Cat BILIARY
MCG0413 A Phase 3 Multicenter, Single-Blind, PETER KAVAN
Randomized Study of XL119 Versus 5-
Fluorouracil (5-FU) plus Leucovorin (LV) in
Subjects with Advanced Biliary Tumors Not
Amenable to Conventional Surgery
Sub-Cat COLORECTAL
MCG0306 An Open-Label, Randomized Phase III Study of RICHARD DALFEN
Intermittent Oral Capecitabine in Combination
with Intravenous Oxaliplatin (Q3W) ("Xelox")
Versus Bolus and Continuous Infusion
Fluorouracil/Intravenous Leucovorin with
Intravenous Oxaliplatin (Q2W) ("FOLFOX") as
Second-Line Treatment for Patients with
Metastatic Colorectal Cancer who have
Received Prior CPT-11 Plus 5-FU+LV as First
Line Therapy.
MCG0325 A RANDOMIZED, DOUBLE-BLIND, PLACEBO- WILSON MILLER
CONTROLLED, PHASE III STUDY IN
PATIENTS WITH METASTATIC
ADENOCARCINOMA OF THE COLON OR
RECTUM WHO ARE RECEIVING FIRST-LINE
CHEMOTHERAPY WITH OXALIPLATIN/5-
FLUOROURACIL/LEUCOVORIN AND
PTK787/222584
MCG0412 An Exploratory Pharmacogenomic Study of MARK BASIK
Erbitux Monotherapy in Patients with Metastatic
Colorectal Carcinoma *On-Hold at MGH. Please
refer patients to Dr. Basik at JGH*
MCG0429 Phase II Study of Neoadjuvant 5- PETER METRAKOS
FU+Leucovorin+CPT-11 in Patients with Liver
Metastases From Colorectal Adenocarcinoma.
MCG0503 First-Line Bevacizumab and Chemotherapy in GERALD BATIST
Metastatic Cancer of the Colon or Rectum: First
Beat (Bevacizumab Expanded Access Trial)
NCICCO.17 A Phase III Randomized Study of Erbitux RICHARD DALFEN
(Cetucimab C225) and Best Supportive Care
Versus Best Supportive Care in Patients with
Pretreated Metastatic Epidermal Growth Factor
Receptor-Positive Colorectal Carcinoma
Sub-Cat PANCREAS
NCICPA.2 Phase III Adjuvant Trial in Pancreatic Cancer WILSON MILLER
Comparing (1) 5-FU and D-L Folinic Acid Versus
(2) Gemcitabine Versus (3) No Adjuvant
Treatment
Sub-Cat RECTAL
MCG0211 A Phase II Study of Using IMRT Radiation for TE VUONG
Patients with Unresectable Recto Sigmoid
Cancer
MCG0324 A Phase I/II Study of Using Pre-Operative High TE VUONG
Dose Rate Brachytherapy for Patients with
Advanced Lower Rectal Cancer in Preparation
for Sphincter Preservation Surgery.
RTOG0315 A Randomized Double Blind, Placebo Controlled LORRAINE
Phase III Study to Determine the Efficacy of PORTELANCE
Sandostatin LAR Deport (Octreotide Acetate) in
Preventing or Reducing the Severity of
Chemoradiation-Induced Diarrhea in Patiets with
Anal or Rectal Cancer
RTOG9811 A Phase III Randomized Study of 5-Fluorouracil, TE VUONG
Mitomycin-C, and Radiotherapy versus 5-
Fluorouracil, Cisplatin, and Radiotherapy in
Carcinoma of the Anal Canal
SITE GU Investigator
Sub-Cat BLADDER
NCICBL.8 Randomized Phase III Trial Comparing RAGHU RAJAN
Immediate Versus Deferred Chemotherapy After
Radical Cystectomy in Patients with pT3-pT4,
and/or N + M0 Transitional Cell Carcinoma
(TCC) of the Bladder
RTOG0233 A Phase II Randomized Trial for Paitnets with LUIS SOUHAMI
Muscle-Invading Bladder Cancer Evaluating
Transurethral Surgery and BID Irradiation Plus
Either Paclitaxel and Cisplatin or 5-Fluorouracil
and Cisplatin Followed by Selective Bladder
Preservation and
Gemcitabine/Paclitaxel/Cisplatin Adjuvant
Chemotherapy.
Sub-Cat PROSTATE
NCICPR.3 Intergroup (NCIC CTG, CUOG, and ECOG) LUIS SOUHAMI
Phase III Randomized Trial Comparing Total
Androgen Blockade versus Total Androgen
Blockade plus Pelvic Irradiation in Clinical Stage
T3-4, NO, MO Adenocarcinoma of the Prostate
NCICPR.8 Intermittent Androgen Deprivation in Patients RAGHU RAJAN
with Stage D2 Prostate Cancer, Phase III Study
RTOG0215 Treatment of Erectile Dysfunction in Patients MARIE DUCLOS
Treated on RTOG 9910 for Prostate Cancer:
Impact on Patients and Partner Quality of Life.
RTOGP-0126 A Phase III Randomized Study of High Dose 3D- MARIE DUCLOS
CRT Versus Standard Dose 3D-CRT in Patients
Treated for Localized Prostate Cancer.
Please contact the Clinical Research Program or at (514) 398-8907, for more information.